| Name | Title | Contact Details |
|---|
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Tactiva is an immuno-oncology company based in Buffalo, New York, utilizing an innovative, dual T cell receptor (TCR) approach to adoptive T cell therapy.
Clinical Data, Inc. is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Uniquely poised as a world class FDA registered outsourcing pharmaceutical manufacturer, Medivant offers the best in the industry when it comes to reliability and management, supply chain transparency, and lower total net cost. *dba Tailstorm Health, Inc. Our vials are made to the exact dosage specification allowing you to achieve a lower net cost of ordering, reducing total waste, and saving you money in the process. Our state of the art manufacturing facility has been completely designed from the ground up with the highest technology available, with full automation, and superior excellence, with highly trained staff experienced in top quality production.
Molecular Templates is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of a next-generation of immunotoxins for the treatment of cancers. Our Engineered Toxin Bodies (ETBs) platform represent a new class of targeted biologic therapies that possess unique biological properties.